Immunogenicity and efficacy of pembrolizumab and doxorubicin in a phase I trial for patients with metastatic triple-negative breast cancer

Currently there is a limited understanding for the optimal combination of immune checkpoint inhibitor and chemotherapy for patients with metastatic triple-negative breast cancer (mTNBC). Here we evaluate the safety, efficacy, and immunogenicity of a phase I trial for patients with mTNBC treated with...

Descripción completa

Detalles Bibliográficos
Autores principales: Egelston, Colt A., Guo, Weihua, Yost, Susan E., Ge, Xuan, Lee, Jin Sun, Frankel, Paul H., Cui, Yujie, Ruel, Christopher, Schmolze, Daniel, Murga, Mireya, Tang, Aileen, Martinez, Norma, Karimi, Misagh, Somlo, George, Lee, Peter P., Waisman, James R., Yuan, Yuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10412661/
https://www.ncbi.nlm.nih.gov/pubmed/37294342
http://dx.doi.org/10.1007/s00262-023-03470-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10412661/
https://www.ncbi.nlm.nih.gov/pubmed/37294342
http://dx.doi.org/10.1007/s00262-023-03470-y

Ejemplares similares